
Highridge Medical commenced U.S. limited launch of the activL Lumbar Disc, along with the successful completion of initial surgeries at multiple disc replacement centers nationwide. The company licensed the U.S. rights to the device in mid-2025.
Early adopters of the disc have expressed confidence in the technology and its clinical performance.
“We are excited to initiate the limited launch of the activL Lumbar Disc and expand access to this important treatment option for surgeons and their patients,” said Rebecca Whitney, CEO of Highridge Medical. “The strong early adoption and positive feedback from leading surgeons validate our strategy to broaden our motion preservation portfolio beyond our market-leading Mobi-C Cervical Disc. We are committed to delivering exceptional service and clinical support as we continue to scale availability.”
Source: Highridge Medical
Highridge Medical commenced U.S. limited launch of the activL Lumbar Disc, along with the successful completion of initial surgeries at multiple disc replacement centers nationwide. The company licensed the U.S. rights to the device in mid-2025.
Early adopters of the disc have expressed confidence in the technology and its clinical...
Highridge Medical commenced U.S. limited launch of the activL Lumbar Disc, along with the successful completion of initial surgeries at multiple disc replacement centers nationwide. The company licensed the U.S. rights to the device in mid-2025.
Early adopters of the disc have expressed confidence in the technology and its clinical performance.
“We are excited to initiate the limited launch of the activL Lumbar Disc and expand access to this important treatment option for surgeons and their patients,” said Rebecca Whitney, CEO of Highridge Medical. “The strong early adoption and positive feedback from leading surgeons validate our strategy to broaden our motion preservation portfolio beyond our market-leading Mobi-C Cervical Disc. We are committed to delivering exceptional service and clinical support as we continue to scale availability.”
Source: Highridge Medical
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





